Peptides for Energy: What the Research Actually Shows

Key Takeaways

• What it is: MOTS-c is a mitochondria-encoded metabolic peptide that regulates AMPK signaling and glucose metabolism; growth hormone secretagogues (GHSs) stimulate pituitary GH release, supporting anabolic and recovery processes.
• Regulatory status: As of April 2026, MOTS-c is not FDA-approved for any indication. Exogenous MOTS-c in injectable form has no legal access pathway in the US. Ipamorelin and CJC-1295 are not FDA-approved; FDA has placed these substances under review and 503A availability varies by jurisdiction and pharmacy. Tesamorelin (Egrifta) is FDA-approved only for HIV-associated lipodystrophy; no FDA-approved sermorelin product is currently marketed, and compounded sermorelin is available by prescription under Section 503A.
• Evidence stage: MOTS-c: multiple animal model and cell culture studies; no completed human efficacy trials as of April 2026. Ipamorelin and CJC-1295: early human pharmacology data from historical drug development programs; no completed adequate and well-controlled efficacy trials for energy, body composition, or recovery endpoints. Sermorelin: historical pediatric GH deficiency and GH-deficiency-evaluation trial data from the original Geref drug development program. Tesamorelin: Phase 3 randomized controlled trial data supporting its approved indication of HIV-associated lipodystrophy; no adequate and well-controlled trials for energy, body composition, or anti-aging indications.
• Regulatory landscape: Peptide bulk drug substances are undergoing significant regulatory change in 2026. FDA actions effective February 2026 and April 22, 2026 have updated the status of multiple peptides referenced in this article. Consult a licensed prescriber for current availability.
• Primary applications studied: MOTS-c: metabolic homeostasis, insulin sensitization, mitochondrial efficiency, aging biology [animal model]. GHSs: GH and IGF-1 stimulation, body composition, sleep quality, lean mass maintenance [early human pharmacology data for unapproved compounds; late-stage data for approved compounds in different indications].

What Is MOTS-c?

MOTS-c (mitochondrial open reading frame of the 12S rRNA type-c) is a 16-amino-acid peptide encoded within the mitochondrial 12S ribosomal RNA gene — an unusual origin for a signaling molecule, since most peptide hormones are encoded in the nuclear genome. Lee and colleagues identified it in 2015, publishing the foundational discovery in Cell Metabolism and showing MOTS-c improves insulin resistance in mice via AMPK/AICAR pathway activation [animal model]. MOTS-c is an endogenous molecule — the body produces it in mitochondria — and circulating plasma levels change with age, metabolic state, and exercise intensity. It belongs to a class of signaling molecules called mitochondrial-derived peptides (MDPs), which also includes humanin and SHLP1-6.

The biological logic underlying interest in MOTS-c for energy is that it operates at the intersection of mitochondrial function and whole-body metabolic regulation — the same systems that underlie cellular energy production. Whether exogenous supplementation of this endogenous molecule produces clinically meaningful effects in humans remains an open question as of April 2026.

Discovery and Background

MOTS-c was identified as part of a broader program investigating whether the mitochondrial genome encodes functional peptide sequences. The discovery that a short reading frame within ribosomal RNA produces a bioactive metabolic regulator was unexpected in 2015. Merry and colleagues' 2020 review in the American Journal of Physiology — Endocrinology and Metabolism reviewed MDPs in metabolic disease. The 2015 discovery paper demonstrated that endogenous MOTS-c levels decline with age and metabolic dysfunction — establishing the same biological rationale for exogenous supplementation that underlies other endogenous peptide therapies. Whether that rationale translates to beneficial human supplementation awaits the human trial data that does not yet exist.

A 2022 review in Ageing Research Reviews described MOTS-c in human aging, noting its visibility in longevity and biohacking communities has been driven by the molecular biology rather than by completed clinical efficacy evidence.

How MOTS-c Works in the Body

MOTS-c acts through multiple metabolic pathways, with AMPK activation as the primary mechanism driving energy-relevant effects. The evidence supporting these mechanisms comes primarily from cell culture and animal model studies.

AMPK activation and mitochondrial efficiency

MOTS-c activates AMP-activated protein kinase (AMPK), a cellular energy sensor that responds to low energy states by upregulating glucose uptake, fatty acid oxidation, and mitochondrial biogenesis while downregulating energy-consuming anabolic processes. AMPK activation is one of several proposed mechanisms associated with metformin's metabolic effects. Shared pathway engagement does not establish that exogenous MOTS-c will produce comparable effects in humans.

Glucose homeostasis and insulin sensitization

For energy-focused readers, the relevant takeaway is that MOTS-c's insulin-sensitizing effects in animal models mean more efficient glucose utilization — which at the cellular level is a component of energy availability.

Exercise interaction and mitochondrial adaptation

Exercise is a documented modulator of circulating MOTS-c levels. A 2021 study in Nature Communications showed MOTS-c and exercise interact synergistically in mice [animal model]. Reynolds and colleagues' 2021 Nature Communications study cited above demonstrated exercise induces MOTS-c in skeletal muscle in mice; Alser and colleagues, in a 2022 study in Reviews in Cardiovascular Medicine, documented altered serum MOTS-c in professional endurance athletes [human observational]. The exercise-MOTS-c interaction is one reason the compound has attracted attention in athletic performance contexts. Whether MOTS-c mediates any of exercise's metabolic benefits in humans has not been demonstrated.

Nuclear translocation and gene regulation

A 2023 review in the Journal of Translational Medicine reviewed MOTS-c stress and aging mechanisms, including nuclear translocation under stress conditions. MOTS-c can translocate to the nucleus and regulate gene expression related to stress responses — a mechanism that extends beyond simple AMPK activation to epigenetic regulation. This nuclear activity is a proposed mechanism for MOTS-c's broader anti-aging effects beyond direct metabolic endpoints [in vitro; animal model].

Growth Hormone Secretagogues and Energy

Growth hormone secretagogues (GHSs) represent a separate category of peptides studied in energy-relevant contexts. Their mechanism is indirect: by stimulating pituitary GH release, they support downstream IGF-1 production and the anabolic processes it mediates — lean mass maintenance, fat metabolism, and recovery — that contribute to what individuals perceive as energy and physical capacity.

Ipamorelin: selective GH secretagogue

Ipamorelin is a synthetic GHRP (growth hormone-releasing peptide) notable for its selectivity. Raun and colleagues' 1998 foundational study in the European Journal of Endocrinology described ipamorelin as a selective GH secretagogue with potency comparable to GHRP-6 and minimal cortisol or prolactin elevation at the doses studied [mixed preclinical and early human pharmacology]. Selectivity matters because cortisol and prolactin elevation from less selective GHRPs can produce adverse effects including metabolic disruption and fatigue. As of April 2026, ipamorelin is not FDA-approved for any indication. FDA has placed ipamorelin under review for the 503A bulks list; availability through 503A compounding pharmacies varies by state pharmacy board, pharmacy-specific practices, and ongoing FDA enforcement posture.

GH/IGF-1 axis and anabolic processes

Kraemer and Ratamess' 2005 review in Sports Medicine reviewed hormonal adaptations to exercise, establishing the hormonal infrastructure that GHSs target. Sigalos and Pastuszak's 2018 review in Sexual Medicine Reviews documented GHS effects on lean mass, bone turnover, sleep quality, and metabolism across clinical populations studied [early human pharmacology data from historical drug development programs]. Growth hormone is primarily secreted during deep sleep, and sleep quality has been reported as an endpoint in some GH-secretagogue studies; whether these effects translate to meaningful recovery improvements in healthy adults has not been established in adequately powered trials.

What the evidence does and does not support

The evidence supporting GHSs for energy specifically is indirect. The compounds produce measurable GH and IGF-1 increases in early human pharmacology studies. The downstream hormonal effects on body composition, recovery, and sleep quality are biologically plausible. But "energy" as a primary endpoint has not been studied in adequately powered, placebo-controlled trials for ipamorelin, CJC-1295, or related unapproved compounds. Long-term safety of GH secretagogues remains uncertain, as noted in the 2018 Sigalos and Pastuszak review in Sexual Medicine Reviews already cited elsewhere in this article — establishing the current-evidence caveat that applies to the entire GHS category for any indication beyond the approved ones.

What the Research Shows

The evidence profile for peptides studied in the energy context spans a wide range of study types, with animal model data substantially stronger than human clinical data for the most-discussed experimental compounds.

In vitro findings (cell-level studies)

In cell culture studies, MOTS-c has been observed to activate AMPK signaling, increase glucose transporter expression, and modulate mitochondrial gene expression. A 2023 study in Molecular Neurobiology showed MOTS-c interacts with Nrf2 in dopaminergic cell culture studies, protecting cells from oxidative stress via antioxidant defense mechanisms [in vitro]. Translation of this in vitro mechanism to human cognitive or energy outcomes has not been demonstrated. These cell-level findings establish biological plausibility. They cannot be directly extrapolated to clinical outcomes in living humans.

Animal model findings

Animal model evidence for MOTS-c is extensive and consistent. Lee and colleagues' original 2015 mouse study demonstrated reduced obesity and improved insulin resistance with systemic MOTS-c administration. Multiple follow-on studies in rodent models reported AMPK activation, enhanced fat oxidation, and improved glucose metabolism. A 2021 study in Cells reviewed secreted peptides in anti-aging, providing broader context for the mitochondrial and longevity peptide landscape. A 2022 study in the Journal of Cellular and Molecular Medicine reported that MOTS-c attenuated pressure-overload cardiac dysfunction in a mouse model [animal model]. Whether exogenous MOTS-c has any cardiovascular effect in humans has not been established. Animal physiology differs from human physiology; these findings do not confirm human efficacy.

Human study findings

As of April 2026, no completed, peer-reviewed human efficacy trials for exogenous MOTS-c supplementation have been published in PubMed. Observational human evidence exists: a 2022 study in Reviews in Cardiovascular Medicine chronic exercise alters serum MOTS-c in professional endurance athletes [human observational], and a 2019 study in the American Journal of Physiology – Renal Physiology documented reduced MOTS-c in CKD patients [human observational]. These observational findings establish that MOTS-c levels correlate with metabolic health status in humans — they do not establish that exogenous supplementation produces the same effects as endogenous levels.

Evidence-level summary

• In vitro (cell culture)
  • Volume of evidence: Extensive
  • Key finding: AMPK activation, glucose metabolism improvement, Nrf2 antioxidant pathway engagement
  • Strength of inference: Establishes biological plausibility only
• Animal models
  • Volume of evidence: Extensive (multiple independent rodent studies)
  • Key finding: Reduced obesity, improved insulin resistance, enhanced fat oxidation, exercise synergy
  • Strength of inference: Supports mechanism; does not confirm human efficacy
• Human observational
  • Volume of evidence: Limited
  • Key finding: Exercise increases circulating MOTS-c; metabolic disease reduces MOTS-c expression
  • Strength of inference: Correlational; no causal inference
• Human RCTs
  • Volume of evidence: None as of April 2026 (for exogenous MOTS-c supplementation)
  • Key finding: No completed trials published
  • Strength of inference: Not yet established

How These Compounds Are Used

Understanding how these compounds are currently used requires distinguishing between legitimate clinical use of approved compounds and the grey-market context for unapproved ones. Compounded preparations are not FDA-approved drug products. Section 503A provides a legal pathway for compounding pharmacies to prepare customized medications; the resulting compounded preparations have not been evaluated by FDA for safety, efficacy, or manufacturing quality in the way that FDA-approved drug products are. Regulatory status for peptide bulk drug substances is undergoing significant change in 2026; FDA actions effective February 2026 and April 22, 2026 have updated the status of multiple peptides referenced in this article.

Sermorelin and tesamorelin

Tesamorelin (Egrifta) is FDA-approved only for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy; use for energy, body composition, or anti-aging purposes is off-label and not addressed in its approved labeling. Sermorelin acetate was previously FDA-approved (as Geref) for GH deficiency evaluation and pediatric GH deficiency treatment; the branded product was withdrawn from the market for commercial reasons, not safety concerns. No FDA-approved sermorelin product is currently marketed. Compounded sermorelin is available through 503A compounding pharmacies by prescription but is not the FDA-approved product; compounded preparations have not been evaluated by FDA for safety, efficacy, or manufacturing quality in the same way that FDA-approved products are.

Ipamorelin and CJC-1295

As of April 2026, ipamorelin and CJC-1295 are not FDA-approved for any indication. FDA has placed these substances under review for inclusion on the 503A bulks list and has raised safety and quality concerns. Some 503A compounding pharmacies continue to compound these peptides; availability varies by state pharmacy board, pharmacy-specific practices, and ongoing FDA enforcement posture. Regulatory status for these peptides is evolving; consult a licensed prescriber for current access information. Products sold online through unregulated vendors operate outside FDA oversight. Products labeled "Research Use Only" or "not for human consumption" sold through online vendors are frequently used for human consumption despite the labeling; FDA considers the totality of context — not just the label — in determining whether a seller is distributing an unapproved drug.

Exogenous MOTS-c

As of April 2026, there is no legal pathway to obtain exogenous MOTS-c for human therapeutic use in the United States. Products labeled as MOTS-c sold through unregulated online vendors are not regulated by the FDA. Superpower does not prescribe, sell, or facilitate access to MOTS-c. Given the absence of human clinical trial data, there is no established safe dose, no characterized adverse event profile, and no clinical basis for recommending exogenous MOTS-c supplementation.

Safety Considerations

The safety considerations for energy-related peptides vary by compound and are limited by the available evidence.

Known adverse effects

Growth hormone secretagogues in clinical contexts have documented adverse effects including fluid retention, joint discomfort, insulin resistance at supraphysiologic GH levels, and potential effects on blood glucose regulation. Sigalos and Pastuszak's 2018 review documented the safety profile of GHSs in clinical use [early human pharmacology data from historical drug development programs]. For MOTS-c, no systematic adverse event data from human trials exists because no human trials have been completed. Animal safety studies have not identified toxicity, but animal safety data does not characterize human adverse event profiles.

Populations who should exercise caution

• Individuals with active or suspected cancer: Growth hormone stimulation carries theoretical concern regarding IGF-1-mediated tumor promotion in individuals with hormone-sensitive malignancies. This is a documented mechanistic concern for GHS compounds.
• Individuals with diabetes or impaired glucose metabolism: Supraphysiologic GH can antagonize insulin signaling. Baseline metabolic assessment is appropriate before any GHS use.
• Competitive athletes: As of the 2026 WADA Prohibited List, growth hormone secretagogues are prohibited in sport. Athletes subject to anti-doping testing should not use these compounds regardless of prescription status.
• Pregnant or breastfeeding individuals: No reproductive safety data exists for any experimental compound discussed in this article.

What is not yet known

Long-term safety data for MOTS-c at any exogenous dose does not exist in the published literature. Drug interaction profiles for all unapproved compounds discussed are unknown. The 2018 Sigalos and Pastuszak review in Sexual Medicine Reviews specifically noted the uncertain long-term safety and efficacy of growth hormone secretagogues as a field-level concern — a gap that applies equally to MOTS-c and related experimental compounds.

How to Access

Tesamorelin (Egrifta) is FDA-approved only for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Use for energy, body composition, or anti-aging purposes is off-label, not addressed in its approved labeling, and not an indication Superpower prescribes tesamorelin for. Compounded sermorelin is available by prescription under Section 503A; it is not the FDA-approved product. Evaluating GH axis function begins with clinical assessment including IGF-1 measurement. Ipamorelin and CJC-1295 are not FDA-approved; 503A availability varies by jurisdiction and pharmacy, and FDA has placed these substances under ongoing review — consult a licensed prescriber for current access information. Exogenous MOTS-c has no legal US access pathway as of April 2026.

Which Biomarkers Are Relevant for Energy Peptide Research?

Understanding your metabolic and hormonal baseline is the logical starting point for anyone curious about energy-related peptide science. The mechanisms MOTS-c and GHSs operate through — AMPK signaling, GH/IGF-1 axis, insulin sensitivity, mitochondrial function — each correspond to measurable markers.

• IGF-1: The primary downstream marker of GH axis activity. IGF-1 levels reflect integrated GH secretion and are the standard monitoring marker for any GH-axis intervention. A baseline reading establishes where the axis stands before any peptide consideration.
• Fasting insulin: A key marker of insulin sensitivity — the metabolic function MOTS-c most consistently improves in animal models. Baseline fasting insulin characterizes insulin resistance status and is among the most clinically informative metabolic markers for energy-related questions.
• Fasting glucose and HbA1c: Complement fasting insulin to provide a full glycemic baseline. AMPK activation improves glucose utilization; knowing baseline fasting glucose and HbA1c contextualizes whether there is a glucose metabolism impairment underlying the energy concern.
• hs-CRP: Inflammatory burden is a significant and often overlooked driver of fatigue. Elevated hs-CRP can suppress mitochondrial function and drive systemic fatigue independently of hormonal or metabolic factors. Knowing this baseline distinguishes metabolic fatigue from inflammatory fatigue before any peptide protocol is considered.
• Thyroid panel (TSH, free T3, free T4): Thyroid dysfunction is among the most common and correctable causes of fatigue. A thyroid baseline rules out the most prevalent explanatory factor before exploring more experimental approaches.
• Comprehensive metabolic panel: Kidney and liver function baselines are appropriate for anyone considering injectable compounds, establishing safety context and organ function status.

The chronic fatigue and recovery biomarker guide covers the full set of markers relevant to understanding the biological drivers of low energy before any intervention is considered.

Knowing where these markers stand before any clinical conversation — about peptides or about any other approach to energy — turns subjective symptom reports into interpretable data. That is the foundation of Superpower's approach to preventive health: understand your biology first, then evaluate the interventions that address what the data actually shows.

IMPORTANT SAFETY INFORMATION

MOTS-c is not approved by the FDA for any medical use. Research on this compound has been limited primarily to laboratory cell culture and animal studies. No completed Phase 1 through Phase 3 human clinical trial data exists for exogenous MOTS-c supplementation as of April 2026. Its safety, efficacy, appropriate dosing, and long-term effects in humans have not been established. MOTS-c is not prescribed, compounded, or dispensed through Superpower. This page is provided for educational purposes only and does not constitute medical advice or an endorsement of use.

Ipamorelin and CJC-1295 are not FDA-approved for any indication. As of April 2026, FDA has placed these substances under review for inclusion on the 503A bulks list; 503A availability varies by state pharmacy board, pharmacy-specific practices, and ongoing FDA enforcement posture. Compounded preparations are not FDA-approved products. As of the 2026 WADA Prohibited List, growth hormone secretagogues including ipamorelin are prohibited in sport. Competitive athletes subject to anti-doping testing should not use these compounds.

Warnings: For growth hormone secretagogues: potential effects on blood glucose regulation; theoretical concern regarding IGF-1-mediated tumor promotion in individuals with active malignancy; no long-term controlled safety trials exist for ipamorelin or CJC-1295 in any indication; sermorelin's safety data comes primarily from its historical FDA approval trials for pediatric GH deficiency and does not characterize long-term adult safety for any off-label indication; tesamorelin's safety data is characterized only for its approved indication of HIV-associated lipodystrophy. For MOTS-c: no human safety data of any kind from clinical trials. Grey-market injectable products lack pharmaceutical-grade manufacturing oversight and carry contamination and dosing risks.

For foundational research background on MOTS-c: Lee et al., 2015, Cell Metabolism — MOTS-c original discovery paper. No FDA-approved prescribing information exists for MOTS-c.

Disclaimer: IMPORTANT: Superpower Health does not prescribe, sell, or facilitate access to MOTS-c, ipamorelin, CJC-1295, or any unapproved peptide. These compounds are not FDA-approved. This page is provided for educational and informational purposes only.